$2.09 billion in sales expected for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) this quarter

Brokers expect Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Get Rating) to report revenue of $2.09 billion for the current quarter, according to Zacks Investment Research. Seven analysts provided earnings estimates for Vertex Pharmaceuticals, with estimates ranging from $1.94 billion to $2.15 billion. Vertex Pharmaceuticals reported sales of $1.72 billion in the same quarter last year, which would indicate a positive year-over-year growth rate of 21.5%. The company is expected to release its next quarterly earnings report on Thursday, May 5.

According to Zacks, analysts expect Vertex Pharmaceuticals to report annual revenue of $8.55 billion in the current fiscal year, with estimates ranging from $8.48 billion to $8.64 billion. of dollars. For the next fiscal year, analysts expect the company to post sales of $9.16 billion, with estimates ranging from $8.84 billion to $9.62 billion. Zacks sales calculations are an average based on a survey of analysts who follow Vertex Pharmaceuticals.

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Rating) last released its quarterly earnings data on Wednesday, January 26. The pharmaceutical company reported earnings per share (EPS) of $3.37 for the quarter, beating analyst consensus estimates of $3.30 by $0.07. Vertex Pharmaceuticals had a return on equity of 32.33% and a net margin of 30.92%. In the same quarter a year earlier, the company posted EPS of $2.22.

(A d)

Do you know which stocks are about to take off in 2022? These are the top 3 growth stocks to watch.
Two of the stocks (in the healthcare/medical sector) could easily reach higher highs over the next 12-18 months.

A number of research companies have commented on VRTX. Evercore ISI reissued a “buy” rating and posted a price target of $265.00 on shares of Vertex Pharmaceuticals in a Thursday, December 23 report. Stifel Nicolaus raised his price target on Vertex Pharmaceuticals from $213.00 to $222.00 and gave the stock a “holding” rating in a Thursday, January 27 research note. Morgan Stanley raised its price target on Vertex Pharmaceuticals from $203.00 to $208.00 and gave the company an “underweight” rating in a Thursday, Jan. 27 research note. TheStreet upgraded Vertex Pharmaceuticals from a “c+” rating to a “b-” rating in a report on Thursday, December 16. Finally, Wells Fargo & Company began covering Vertex Pharmaceuticals in a Wednesday, Dec. 8 report. They set an “overweight” rating and a price target of $270.00 for the company. Three analysts gave the stock a sell rating, five gave the company a hold rating and eleven gave the company a buy rating. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $256.67.

NASDAQ VRTX opened at $234.11 on Thursday. Vertex Pharmaceuticals has a fifty-two week low of $176.36 and a fifty-two week high of $254.93. The company has a debt ratio of 0.05, a quick ratio of 3.56 and a current ratio of 3.71. The stock has a 50-day simple moving average of $230.90 and a two-hundred-day simple moving average of $205.35. The stock has a market capitalization of $59.60 billion, a P/E ratio of 25.93, a price-to-earnings growth ratio of 1.39 and a beta of 0.64.

In other news, Executive Vice President David Altshuler sold 2,297 shares of the company in a trade that took place on Friday, February 11. The shares were sold at an average price of $235.02, for a total transaction of $539,840.94. The sale was disclosed in a filing with the Securities & Exchange Commission, accessible via this link. Additionally, Executive Vice President Ourania Tatsis sold 325 shares of the company in a transaction that took place on Friday, February 25. The stock was sold at an average price of $230.95, for a total transaction of $75,058.75. The disclosure of this sale can be found here. Insiders sold a total of 12,125 shares of the company worth $2,940,964 in the past 90 days. Insiders hold 0.30% of the shares of the company.

A number of institutional investors have been buying and selling shares of VRTX recently. Stonebridge Capital Advisors LLC acquired a new stake in Vertex Pharmaceuticals in Q2 worth approximately $26,000. Concord Wealth Partners increased its stake in Vertex Pharmaceuticals by 750.0% in the fourth quarter. Concord Wealth Partners now owns 119 shares of the pharmaceutical company valued at $26,000 after buying 105 additional shares in the last quarter. First PREMIER Bank acquired a new stake in Vertex Pharmaceuticals in Q4 valued at approximately $27,000. Hudock Inc. increased its stake in Vertex Pharmaceuticals by 156.3% in Q3. Hudock Inc. now owns 164 shares of the pharmaceutical company valued at $29,000 after buying 100 more shares in the last quarter. Finally, Moors & Cabot Inc. acquired a new stake in Vertex Pharmaceuticals in Q3 valued at approximately $29,000. Hedge funds and other institutional investors own 89.69% of the company’s shares.

Vertex Pharmaceuticals Company Profile (Get a rating)

Vertex Pharmaceuticals, Inc. is a global biotechnology company. It is dedicated to the discovery, development, manufacture and commercialization of small molecule drugs for patients with serious diseases. The company is focused on developing and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis.

Read more

Get a Free Copy of Zacks’ Research Report on Vertex Pharmaceuticals (VRTX)

For more information on Zacks Investment Research’s research offerings, visit Zacks.com

Earnings history and estimates for Vertex Pharmaceuticals (NASDAQ:VRTX)

This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]

Should you invest $1,000 in Vertex Pharmaceuticals right now?

Before you consider Vertex Pharmaceuticals, you’ll want to hear this.

MarketBeat tracks Wall Street’s top-rated, top-performing research analysts daily and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes hold…and Vertex Pharmaceuticals was not on the list.

Although Vertex Pharmaceuticals currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.

See the 5 actions here

Comments are closed.